Key facts
- ProVascTec’s last known valuation is $6.7M.
- It has raised $3.5M; the latest was Early Stage VC in Jul 2025.
- Notable investors include Creative Destruction Lab, Enterprise Ireland, NLC Health Ventures, University College Cork, Eurostars.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for ProVascTec
- ·The full record, as it builds
Funding rounds
No funding rounds for ProVascTec are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ProVascTec
Operator of a cell therapy company intended to positively impact the lives of patients suffering from cardiovascular complications. The company leverages the paracrine mechanism of stem cells to induce the growth of a novel vascular system, creating a natural bypass around arterial occlusions in the peripheral vascular system, specifically below the knee, providing healthcare professionals with a proprietary local delivery device.
- Sector
- Healthcare
- HQ
- Cork, Ireland
- Founded
- 2021
- Employees
- 3
- Website
- provasctec.com/
- Ownership
- Privately Held (backing)
ProVascTec doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ProVascTec shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ProVascTec in its N-PORT filings yet. We sweep new filings monthly.